{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:10:34Z","timestamp":1787065834341,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T00:00:00Z","timestamp":1754870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00972-6","type":"journal-article","created":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T14:44:17Z","timestamp":1754923457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Safety profile of belatacept in a real-life setting: disproportionality analysis of the WHO pharmacovigilance database"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6591-6966","authenticated-orcid":false,"given":"Alexandre O.","family":"G\u00e9rard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7669-2339","authenticated-orcid":false,"given":"Diane","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouha","family":"Ben Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Destere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Viard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elliot","family":"Ewig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Rocher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3427-3894","authenticated-orcid":false,"given":"Antoine","family":"Sicard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-530X","authenticated-orcid":false,"given":"Milou-Daniel","family":"Drici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,11]]},"reference":[{"key":"972_CR1","doi-asserted-by":"crossref","unstructured":"Lombardi Y, Fran\u00e7ois H. Belatacept in kidney transplantation: what are the true benefits? A systematic review. Front Med. 2022;9.","DOI":"10.3389\/fmed.2022.942665"},{"key":"972_CR2","doi-asserted-by":"publisher","first-page":"14412","DOI":"10.3389\/ti.2025.14412","volume":"38","author":"J Noble","year":"2025","unstructured":"Noble J, Leon J, Del Bello A, Anglicheau D, Blancho G, Ville S, et al. Belatacept in kidney transplantation: reflecting on the past, shaping the future. Transpl Int. 2025;38:14412.","journal-title":"Transpl Int"},{"key":"972_CR3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1053\/j.ajkd.2016.09.021","volume":"69","author":"JM Griny\u00f3","year":"2017","unstructured":"Griny\u00f3 JM, Del Carmen Rial M, Alberu J, Steinberg SM, Manfro RC, Nainan G, et al. Safety and efficacy outcomes 3 years after switching to Belatacept from a calcineurin inhibitor in kidney transplant recipients: results from a phase 2 randomized trial. Am J Kidney Dis Off J Natl Kidney Found. 2017;69:587\u201394.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"972_CR4","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1097\/TP.0000000000002192","volume":"102","author":"A Darres","year":"2018","unstructured":"Darres A, Ulloa C, Brakemeier S, Garrouste C, Bestard O, Del Bello A, et al. Conversion to Belatacept in maintenance kidney transplant patients: A retrospective multicenter European study. Transplantation. 2018;102:1545\u201352.","journal-title":"Transplantation"},{"key":"972_CR5","doi-asserted-by":"publisher","first-page":"e517","DOI":"10.1097\/TXD.0000000000000964","volume":"6","author":"F Terrec","year":"2019","unstructured":"Terrec F, Jouve T, Naciri-Bennani H, Benhamou P-Y, Malvezzi P, Janbon B, et al. Late conversion from calcineurin inhibitors to Belatacept in Kidney-Transplant recipients has a significant beneficial impact on glycemic parameters. Transpl Direct. 2019;6:e517.","journal-title":"Transpl Direct"},{"key":"972_CR6","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/j.ekir.2020.09.036","volume":"5","author":"A Gouin","year":"2020","unstructured":"Gouin A, Sberro-Soussan R, Courivaud C, Bertrand D, Del Bello A, Darres A, et al. Conversion from Belatacept to another immunosuppressive regimen in maintenance Kidney-Transplantation patients. Kidney Int Rep. 2020;5:2195\u2013201.","journal-title":"Kidney Int Rep"},{"key":"972_CR7","unstructured":"EMA. Nulojix - Summary of Product Characteristics."},{"key":"972_CR8","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","volume":"10","author":"F Vincenti","year":"2010","unstructured":"Vincenti F, Charpentier B, Vanrenterghem Y, Rostaing L, Bresnahan B, Darji P, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg. 2010;10:535\u201346.","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"972_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40472-025-00481-9","volume":"12","author":"DA Faber","year":"2025","unstructured":"Faber DA, Vasanth P, Larsen CP, Tso P, Badell IR. Current use of Belatacept in kidney transplantation: A review of historical use and modern trends. Curr Transpl Rep. 2025;12:25.","journal-title":"Curr Transpl Rep"},{"key":"972_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/TP.0000000000005196","volume":"109","author":"J Yamauchi","year":"2025","unstructured":"Yamauchi J, Raghavan D, Jweehan D, Oygen S, Marineci S, Hall IE, et al. Belatacept versus tacrolimus for kidney transplant recipients of deceased donors with acute kidney injury: US National database study. Transplantation. 2025;109:691.","journal-title":"Transplantation"},{"key":"972_CR11","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/ajt.16132","volume":"21","author":"G Karadkhele","year":"2021","unstructured":"Karadkhele G, Hogan J, Magua W, Zhang W, Badell IR, Mehta A, et al. CMV high-risk status and posttransplant outcomes in kidney transplant recipients treated with Belatacept. Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg. 2021;21:208\u201321.","journal-title":"Am J Transpl Off J Am Soc Transpl Am Soc Transpl Surg"},{"key":"972_CR12","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.ajt.2024.09.035","volume":"25","author":"J Zuber","year":"2025","unstructured":"Zuber J, Leon J, D\u00e9chanet-Merville J, Kaminski H. Belatacept-related cytomegalovirus infection: advocacy for tailored immunosuppression based on individual assessment of immune fitness. Am J Transpl. 2025;25:277\u201383.","journal-title":"Am J Transpl"},{"key":"972_CR13","doi-asserted-by":"publisher","first-page":"e14403","DOI":"10.1111\/tid.14403","volume":"27","author":"MR Heldman","year":"2025","unstructured":"Heldman MR, Saullo JL, Menachem BM, Messina JA, Arif S, Steinbrink JM, et al. Epidemiology of infections in lung transplant recipients treated with Belatacept. Transpl Infect Dis. 2025;27:e14403.","journal-title":"Transpl Infect Dis"},{"key":"972_CR14","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1097\/TP.0000000000001763","volume":"101","author":"S Gabardi","year":"2017","unstructured":"Gabardi S, van Gelder T. Causes and consequences of the worldwide Belatacept shortage. Transplantation. 2017;101:1520\u20131.","journal-title":"Transplantation"},{"key":"972_CR15","doi-asserted-by":"publisher","first-page":"1514033","DOI":"10.3389\/fimmu.2025.1514033","volume":"16","author":"AO G\u00e9rard","year":"2025","unstructured":"G\u00e9rard AO, Merino D, Benzaquen J, Destere A, Borchiellini D, Gosset C, et al. PDL1 inhibitors May be associated with a lower risk of allograft rejection than PD1 and CTLA4 inhibitors: analysis of the WHO pharmacovigilance database. Front Immunol. 2025;16:1514033.","journal-title":"Front Immunol"},{"key":"972_CR16","unstructured":"VigiBase. Oct. UMC| Analytics in VigiLyze. https:\/\/www.who-umc.org\/vigibase\/vigilyze\/analytics-in-vigilyze\/. Accessed 11 2022."},{"key":"972_CR17","unstructured":"MedDRA. MedDRA Hierarchy| MedDRA. https:\/\/www.meddra.org\/how-to-use\/basics\/hierarchy. Accessed 3 Sep 2021."},{"key":"972_CR18","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.transproceed.2020.11.001","volume":"53","author":"M Yazdi","year":"2021","unstructured":"Yazdi M, Kahwaji JM, Meguerditchian S, Lee R. Belatacept conversion protocols and outcomes in kidney transplant recipients. Transpl Proc. 2021;53:976\u201383.","journal-title":"Transpl Proc"},{"key":"972_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement. Drug Saf. 2024;47:575\u201384.","journal-title":"Drug Saf"},{"key":"972_CR20","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting: QUANTITATIVE SIGNAL DETECTION. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"972_CR21","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1111\/ajt.13698","volume":"16","author":"Y Le Meur","year":"2016","unstructured":"Le Meur Y, Aulagnon F, Bertrand D, Heng AE, Lavaud S, Caillard S, et al. Effect of an early switch to Belatacept among calcineurin Inhibitor\u2013Intolerant graft recipients of kidneys from Extended-Criteria donors. Am J Transpl. 2016;16:2181\u20136.","journal-title":"Am J Transpl"},{"key":"972_CR22","doi-asserted-by":"publisher","first-page":"e13170","DOI":"10.1111\/tid.13170","volume":"21","author":"M Cambier","year":"2019","unstructured":"Cambier M, Canestri A, Lependeven C, Peltier J, Mesnard L, Dahan K. Hepatitis B virus reactivation during Belatacept treatment after kidney transplantation. Transpl Infect Dis. 2019;21:e13170.","journal-title":"Transpl Infect Dis"},{"key":"972_CR23","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/j.ekir.2023.05.005","volume":"8","author":"C Schwarz","year":"2023","unstructured":"Schwarz C, Morel A, Matignon M, Grimbert P, Rondeau E, Ouali N, et al. Hepatitis B virus reactivation in kidney transplant recipients treated with Belatacept. Kidney Int Rep. 2023;8:1531\u201341.","journal-title":"Kidney Int Rep"},{"key":"972_CR24","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1600-6143.2008.02482.x","volume":"9","author":"N Ashman","year":"2009","unstructured":"Ashman N, Chapagain A, Dobbie H, Raftery MJ, Sheaff MT, Yaqoob MM. Belatacept as maintenance immunosuppression for postrenal transplant de Novo Drug-Induced thrombotic microangiopathy. Am J Transpl. 2009;9:424\u20137.","journal-title":"Am J Transpl"},{"key":"972_CR25","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1681\/ASN.20233411S1614b","volume":"34","author":"MCVM Capistrano","year":"2023","unstructured":"Capistrano MCVM, Agarwal KA. Post-Transplant thrombotic microangiopathy: A miraculous outcome with Eculizumab and belatacept: FR-PO760. J Am Soc Nephrol. 2023;34:614.","journal-title":"J Am Soc Nephrol"},{"key":"972_CR26","doi-asserted-by":"crossref","unstructured":"Zafar M, Rajan RM, Ahmed RT, Reddy A. Disseminated histoplasmosis with secondary hemophagocytic lymphohistiocytosis in a renal transplant recipient on Belatacept-based immunosuppression. J Brown Hosp Med. 2024;3.","DOI":"10.56305\/001c.118963"},{"key":"972_CR27","doi-asserted-by":"publisher","first-page":"e13732","DOI":"10.1111\/tid.13732","volume":"23","author":"E Vald\u00e9s Franc\u00ed","year":"2021","unstructured":"Vald\u00e9s Franc\u00ed E, Perez Flores I, Candel FJ, De La Higuera M, Romero MA, Rodr\u00edguez Cubillo NC. Hemophagocytic syndrome triggered by donor-transmitted toxoplasmosis as a complication in same\u2010donor recipients of renal transplantation: case report and review of the literature. Transpl Infect Dis. 2021;23:e13732.","journal-title":"Transpl Infect Dis"},{"key":"972_CR28","doi-asserted-by":"publisher","first-page":"e1368","DOI":"10.1097\/TXD.0000000000001368","volume":"8","author":"S Mazzola Poli de Figueiredo","year":"2022","unstructured":"Mazzola Poli de Figueiredo S, Johnson JC, Lyapichev KA, Stevenson HL, Lea A, Hussain S, et al. Fatal case of EBV-negative posttransplant lymphoproliferative disorder with hemophagocytic lymphohistiocytosis in an adult kidney transplant recipient. Transpl Direct. 2022;8:e1368.","journal-title":"Transpl Direct"},{"key":"972_CR29","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ijgo.13819","volume":"157","author":"A Kallapur","year":"2022","unstructured":"Kallapur A, Jang C, Yin O, Mei JY, Afshar Y. Pregnancy care in solid organ transplant recipients. Int J Gynecol Obstet. 2022;157:502\u201313.","journal-title":"Int J Gynecol Obstet"},{"key":"972_CR30","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1111\/j.1600-6143.2011.03656.x","volume":"11","author":"NA Deshpande","year":"2011","unstructured":"Deshpande NA, James NT, Kucirka LM, Boyarsky BJ, Garonzik-Wang JM, Montgomery RA, et al. Pregnancy outcomes in kidney transplant recipients: A systematic review and Meta-Analysis. Am J Transpl. 2011;11:2388\u2013404.","journal-title":"Am J Transpl"},{"key":"972_CR31","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1093\/ckj\/sfab049","volume":"14","author":"H Boulay","year":"2021","unstructured":"Boulay H, Mazaud-Guittot S, Supervielle J, Chemouny JM, Dardier V, Lacroix A, et al. Maternal, foetal and child consequences of immunosuppressive drugs during pregnancy in women with organ transplant: a review. Clin Kidney J. 2021;14:1871\u20138.","journal-title":"Clin Kidney J"},{"key":"972_CR32","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1097\/TP.0000000000004634","volume":"107","author":"L Coscia","year":"2023","unstructured":"Coscia L, Cohen D, Dube GK, Hofmann RM, Moritz MJ, Gattis S, et al. Outcomes with Belatacept exposure during pregnancy in kidney transplant recipients: A case series. Transplantation. 2023;107:2047\u201354.","journal-title":"Transplantation"},{"key":"972_CR33","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.ekir.2025.03.016","volume":"10","author":"C Duneton","year":"2025","unstructured":"Duneton C, George R, Liverman R, Sellier-Leclerc A-L, Beauval B, Baudouin V, et al. One-Year outcomes after Belatacept conversion in adolescent kidney transplant recipients. Kidney Int Rep. 2025;10:1795\u2013805.","journal-title":"Kidney Int Rep"},{"key":"972_CR34","unstructured":"European Commission. A guideline on summary of product characteristics (SmPC). 2009."},{"key":"972_CR35","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2165\/00002018-199716060-00002","volume":"16","author":"RHB Meyboom","year":"1997","unstructured":"Meyboom RHB, Egberts ACG, Edwards IR, Hekster YA, de Koning FHP, Gribnau FWJ. Principles of signal detection in pharmacovigilance. Drug Saf. 1997;16:355\u201365.","journal-title":"Drug Saf"},{"key":"972_CR36","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1080\/14740338.2024.2368817","volume":"23","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Raschi E, Poluzzi E, Hauben M. The evolving role of disproportionality analysis in pharmacovigilance. Expert Opin Drug Saf. 2024;23:981\u201394.","journal-title":"Expert Opin Drug Saf"},{"key":"972_CR37","unstructured":"Bristol-Myers Squibb. Phase II-III, Open-Label. Randomized, controlled, Multiple-Dose study of efficacy and safety of BMS-224818 (Belatacept) as part of a quadruple drug regimen in first renal transplant recipients. Clinical trial registration. 2013. clinicaltrials.gov"},{"key":"972_CR38","unstructured":"Bristol-Myers Squibb. Belatacept evaluation of nephroprotection and efficacy as First-line immunosuppression trial (BENEFIT). Clinical trial registration. 2016. clinicaltrials.gov"},{"key":"972_CR39","unstructured":"Bristol-Myers Squibb. Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial - Extended Criteria Donors (BENEFIT-EXT). Clinical trial registration. 2017. clinicaltrials.gov"},{"key":"972_CR40","doi-asserted-by":"publisher","first-page":"8660","DOI":"10.3748\/wjg.v23.i48.8660","volume":"23","author":"A Bozon","year":"2017","unstructured":"Bozon A, Jeantet G, Rivi\u00e8re B, Funakoshi N, Dufour G, Combes R, et al. Stricturing crohn\u2019s disease-like colitis in a patient treated with Belatacept. World J Gastroenterol. 2017;23:8660\u20135.","journal-title":"World J Gastroenterol"},{"key":"972_CR41","doi-asserted-by":"publisher","first-page":"e355","DOI":"10.1097\/TP.0000000000002247","volume":"102","author":"S Ville","year":"2018","unstructured":"Ville S, Cantarovich D. Belatacept and autoimmune adverse events. Transplantation. 2018;102:e355\u20136.","journal-title":"Transplantation"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00972-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00972-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00972-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T23:21:00Z","timestamp":1757373660000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00972-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,11]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["972"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00972-6","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,11]]},"assertion":[{"value":"11 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AS has been paid as a consultant by Bristol-Myers Squibb, the company that markets Nulojix\n                      \u00ae\n                      . The other authors declare no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"147"}}